• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Hematology Association - 30th Congress Milan Italy

June 12 - 17, 2025

  1. HSCT-TMA 
  2. PNH

pdf

Exposure response of ravulizumab to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy

pdf

Ravulizumab plus best supportive care to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy: first results from a phase 3 trial

html

Assessment of long-term renal function in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab in a phase 3 open-label study

html

A real-world, multi-center, prospective, observational study for paroxysmal nocturnal hemoglobinuria (PNH) in China: preliminary results

pdf

Both rare PNH cells and minor PNH clones should be considered as genuine PNH clones: insights from analysis of the 5-year French nation-wide multicenter observational study

pdf 

Danicopan add-on to ravulizumab or eculizumab in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis stratified by bone marrow failure history

pdf 

High proportion of PNH type II neutrophils, i.e relative percentage ≥3%, Is associated with thrombosis in patients displaying a PNH clone >1%: evidence from analysis of the 5-Year french nation-wide Multicenter observational study

html

Real-world effectiveness of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: The US POLESTAR chart review study

pdf 

Sustained long-term control of terminal complement activity with ravulizumab or danicopan add-on to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice